In vitro–in vivo evaluation of poly(2-hydroxyethyl methacrylate-co-methyl methacrylate) hydrogel implants containing cisplatin

The aim of this study was to prepare hydrogel disc implants containing cisplatin from hydroxyethyl methacrylate (HEMA) and methyl methacrylate (MMA). To control drug release, the monomers were cross-linked with ethyleneglycol dimethacrylate (EGDMA). Implants were characterized by FTIR, DSC and SEM a...

Full description

Bibliographic Details
Main Authors: Madhu Babu, Hemant K.S. Yadav, Afrasim Moin, Hosakote G. Shivakumar
Format: Article
Language:English
Published: Elsevier 2011-12-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383511000803
id doaj-d009836210c944dfa9a6452a2bbe7301
record_format Article
spelling doaj-d009836210c944dfa9a6452a2bbe73012020-11-24T22:19:21ZengElsevierActa Pharmaceutica Sinica B2211-38352211-38432011-12-011426126710.1016/j.apsb.2011.09.001In vitro–in vivo evaluation of poly(2-hydroxyethyl methacrylate-co-methyl methacrylate) hydrogel implants containing cisplatinMadhu BabuHemant K.S. YadavAfrasim MoinHosakote G. ShivakumarThe aim of this study was to prepare hydrogel disc implants containing cisplatin from hydroxyethyl methacrylate (HEMA) and methyl methacrylate (MMA). To control drug release, the monomers were cross-linked with ethyleneglycol dimethacrylate (EGDMA). Implants were characterized by FTIR, DSC and SEM and evaluated for drug content, swelling, tensile strength, in vitro and in vivo drug release, in vitro and in vivo biodegradation of the polymer and histopathological studies. The in vitro results showed that increasing the concentration of either MMA or EGDMA decreased drug release and prolonged the implant life. Histopathological studies showed that the implants were histocompatible with surrounding tissue. Stability studies on the optimized formulation showed it was stable over 90 days at 25±3 °C. The implants can be used to achieve controlled release of drug and attain effective treatment with reduced side effects.http://www.sciencedirect.com/science/article/pii/S2211383511000803Controlled releaseSwellingHistocompatibleBiodegradation
collection DOAJ
language English
format Article
sources DOAJ
author Madhu Babu
Hemant K.S. Yadav
Afrasim Moin
Hosakote G. Shivakumar
spellingShingle Madhu Babu
Hemant K.S. Yadav
Afrasim Moin
Hosakote G. Shivakumar
In vitro–in vivo evaluation of poly(2-hydroxyethyl methacrylate-co-methyl methacrylate) hydrogel implants containing cisplatin
Acta Pharmaceutica Sinica B
Controlled release
Swelling
Histocompatible
Biodegradation
author_facet Madhu Babu
Hemant K.S. Yadav
Afrasim Moin
Hosakote G. Shivakumar
author_sort Madhu Babu
title In vitro–in vivo evaluation of poly(2-hydroxyethyl methacrylate-co-methyl methacrylate) hydrogel implants containing cisplatin
title_short In vitro–in vivo evaluation of poly(2-hydroxyethyl methacrylate-co-methyl methacrylate) hydrogel implants containing cisplatin
title_full In vitro–in vivo evaluation of poly(2-hydroxyethyl methacrylate-co-methyl methacrylate) hydrogel implants containing cisplatin
title_fullStr In vitro–in vivo evaluation of poly(2-hydroxyethyl methacrylate-co-methyl methacrylate) hydrogel implants containing cisplatin
title_full_unstemmed In vitro–in vivo evaluation of poly(2-hydroxyethyl methacrylate-co-methyl methacrylate) hydrogel implants containing cisplatin
title_sort in vitro–in vivo evaluation of poly(2-hydroxyethyl methacrylate-co-methyl methacrylate) hydrogel implants containing cisplatin
publisher Elsevier
series Acta Pharmaceutica Sinica B
issn 2211-3835
2211-3843
publishDate 2011-12-01
description The aim of this study was to prepare hydrogel disc implants containing cisplatin from hydroxyethyl methacrylate (HEMA) and methyl methacrylate (MMA). To control drug release, the monomers were cross-linked with ethyleneglycol dimethacrylate (EGDMA). Implants were characterized by FTIR, DSC and SEM and evaluated for drug content, swelling, tensile strength, in vitro and in vivo drug release, in vitro and in vivo biodegradation of the polymer and histopathological studies. The in vitro results showed that increasing the concentration of either MMA or EGDMA decreased drug release and prolonged the implant life. Histopathological studies showed that the implants were histocompatible with surrounding tissue. Stability studies on the optimized formulation showed it was stable over 90 days at 25±3 °C. The implants can be used to achieve controlled release of drug and attain effective treatment with reduced side effects.
topic Controlled release
Swelling
Histocompatible
Biodegradation
url http://www.sciencedirect.com/science/article/pii/S2211383511000803
work_keys_str_mv AT madhubabu invitroinvivoevaluationofpoly2hydroxyethylmethacrylatecomethylmethacrylatehydrogelimplantscontainingcisplatin
AT hemantksyadav invitroinvivoevaluationofpoly2hydroxyethylmethacrylatecomethylmethacrylatehydrogelimplantscontainingcisplatin
AT afrasimmoin invitroinvivoevaluationofpoly2hydroxyethylmethacrylatecomethylmethacrylatehydrogelimplantscontainingcisplatin
AT hosakotegshivakumar invitroinvivoevaluationofpoly2hydroxyethylmethacrylatecomethylmethacrylatehydrogelimplantscontainingcisplatin
_version_ 1725779573538291712